Valproic acid sodium (GMP)
Based on 1 Customer Validation
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
For research use only. We do not sell to patients.
- CAS No.: 1069-66-5
- Formula: C8H15NaO2
- Molecular Weight:166.19
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Endogenous Metabolite Isoforms
More
Biological Activity
Valproic acid (VPA) (0-15 mM; 24 and 72 h) inhibits Hela cell growth in a dose- and time- dependent manner[1].
Valproic acid (10 mM; 24 h) significantly attenuates the activities of total, cytosol and nuclear HDACs[1].
Valproic acid (0-15 mM; 24 h) induces a G1 phase arrest at 1–3 mM and a G2/M phase arrest at 10 mM, and increases the percentage of sub-G1 cells in HeLa cells. Valproic acid also induces necrosis, apoptosis and lactate dehydrogenase (LDH) release[1].
Valproic acid (0-20 mM; 24 h) activates Tcf/Lef-dependent transcription and synergizes with lithium[2].
Valproic acid (0-5 mM; 0-18 h) increases β-catenin levels in Neuro2A cells[2].
Valproic acid (0-2 mM; 0-24 h) stimulates phosphorylation of AMPK and ACC in hepatocytes[5].
Valproic acid (0-10 mM; 2 days) induces Notch1 signaling and morphologic differentiation, suppresses production of NE tumor markers in SCLC cells[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HeLa cells
-
Concentration:0, 1, 3, 5, 10 and 15 mM
-
Incubation Time:24 and 72 h
-
Result:HeLa cell growth was dose- and time-dependently decreased with an IC50 of ~10 and 4 mM at 24 and 72 h.
-
Cell Line:HeLa cells, Neuro2A cells or primary mouse hepatocytes
-
Concentration:10 mM (HeLa); 0, 2, and 5 mM (Neuro2A); 0.2, 0.4, 0.8, 1.2 and 2 mM (hepatocytes)
-
Incubation Time:24 h (HeLa); 0-18 h (Neuro2A); 0-24 h (hepatocytes)
-
Result:Increased the form of acetylated histone 3.
Reduced PARP, induced cleavage PARP, and downregulated Bcl-2.
Increased β-catenin levels.
Increased the phosphorylation of AMPK and ACC.
-
Cell Line:HeLa cells
-
Concentration:0, 1, 3, 5, 10 and 15 mM
-
Incubation Time:24 h
-
Result:Induced a G1 phase arrest at 1–3 mM, significantly induced a G2/M phase arrest at 10 mM, and increased the percentage of sub-G1 cells in HeLa cells in a dose-dependent manner at 24 h.
Valproic acid (350 mg/kg; i.p.; once) enhances social behavior in rats[4].
Valproic acid (0.26% (w/v); p.o. via drinking water; 14 days) decreases liver mass, hepatic fat accumulation, and serum glucose in obese mice without hepatotoxicity[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c nude mice, Kasumi-1 tumor model[3]
-
Dosage:500 mg/kg
-
Administration:Intraperitoneal injection, daily for 12 days
-
Result:Inhibited tumor growth and tumor angiogenesis.
Inhibited the mRNA and protein expression of VEGF, VEGFR2 and bFGF.
Inhibited HDAC activity and increased acetylation of histone H3.
Enhanced the accumulation of hyperacetylated histone H3 on VEGF promoters.
-
Animal Model:Timed-pregnant Long Evans rats[4]
-
Dosage:350 mg/kg
-
Administration:Intraperitoneal injection, once
-
Result:Demonstrated more social investigation and play fighting than control animals.
-
Animal Model:Obese phenotype of ob/ob mice[5]
-
Dosage:0.26% (w/v)
-
Administration:Oral via drinking water, 14 days
-
Result:Revealed a marked reduction in the accumulation of fats in the liver as compared with the untreated mice, significantly decreased liver mass to body mass, decreased serum triglyceride concentrations, and did not induce hepatotoxicity.
Chemical Information
-
CAS No. 1069-66-5
-
Appearance Solid
-
Molecular Weight 166.19
-
Formula C8H15NaO2
-
Color White to off-white
-
SMILES
O=C(O[Na])C(CCC)CCC
-
Synonyms
Sodium Valproate (GMP); VPA sodium (GMP); 2-Propylpentanoic acid sodium (GMP)
-
Shipping
Shipping with dry ice.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Han BR, et al. Valproic acid inhibits the growth of HeLa cervical cancer cells via caspase-dependent apoptosis. Oncol Rep. 2013 Dec;30(6):2999-3005. [Content Brief]
[2]. Valproic acid, et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001 Sep 28;276(39):36734-41. [Content Brief]
[3]. Zhang ZH, et al. Valproic acid inhibits tumor angiogenesis in mice transplanted with Kasumi 1 leukemia cells. Mol Med Rep. 2013 Nov 28. [Content Brief]
[4]. Cohen OS, et al. Acute prenatal exposure to a moderate dose of valproic acid increases social behavior and alters gene expression in rats. Int J Dev Neurosci. 2013 Dec;31(8):740-50. [Content Brief]
[5]. Avery LB, et al. Valproic Acid Is a Novel Activator of AMP-Activated Protein Kinase and Decreases Liver Mass, Hepatic Fat Accumulation, and Serum Glucose in Obese Mice. Mol Pharmacol. 2014 Jan;85(1):1-10. [Content Brief]
[6]. Platta CS, et al. Valproic acid induces Notch1 signaling in small cell lung cancer cells. J Surg Res. 2008 Jul;148(1):31-7. [Content Brief]
[7]. Routy JP, et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med. 2012 May;13(5):291-6. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Valproic acid sodium (GMP) Related Classifications
Cat. No.: HY-10585AG
Powered by Bioz
- Valproic acid sodium (GMP)
- 1069-66-5
- Sodium Valproate (GMP)
- VPA sodium (GMP)
- 2-Propylpentanoic acid sodium (GMP)
- Organoid
- HDAC
- Autophagy
- Mitophagy
- HIV
- Notch
- Apoptosis
- Endogenous Metabolite
- Hela
- proteasomal
- degradation
- Notch1
- SCLC
- epilepsy
- bipolar disorder
- migraine
- headaches
- small cell lung cancer
- anticancer
- anticonvulsant
- hepatic fat accumulation
- Inhibitor
- inhibitor
- inhibit